22:41 , Nov 8, 2018 |  BC Innovations  |  Product R&D

JLABS seeks lung cancer solutions in Shanghai

As Johnson & Johnson gears up to launch its Shanghai JLABS site early next year, the incubator’s head, Sharon Chan, has pegged lung cancer as one of the first priorities. Chan sees opportunity in China...
07:00 , Sep 28, 2015 |  BC Week In Review  |  Clinical News

ID93/GLA-SE: Phase IIa started

IDRI began a double-blind, dose-escalation, South African Phase IIa trial to evaluate intramuscular ID93 with GLA-SE at days 0 and 56 in about 60 adult patients who have successfully completed TB treatment with confirmed bacteriologic...
08:00 , Nov 13, 2014 |  BC Innovations  |  Cover Story

Boosting adjuvants

For all the talk of new vaccines, not much attention has been paid to the need for better adjuvants, which have remained stuck on alum-based products for decades. The NIH is committing up to $70...
07:00 , Jun 2, 2014 |  BC Week In Review  |  Company News

Japan BCG, Dainippon Sumitomo, Innovation Network Corp. deal

Innovation Network, vaccine company Japan BCG and Dainippon said they made a new joint investment of ¥845 million ($8.3 million) in Create Vaccine Co. Ltd. to fund preclinical development of mucosal tuberculosis (TB) vaccines. The...
07:00 , Apr 17, 2014 |  BC Innovations  |  Translation in Brief

Translational tidbits

AstraZeneca plc had a busy March, announcing five new public-private partnerships and the launch of its Open Innovation website to list additional partnership opportunities ( see "Selected public-private partnerships for March 2014"). One of the...
07:00 , Mar 24, 2014 |  BC Week In Review  |  Clinical News

AERAS-404: Phase II started

Aeras began a partially blind South African Phase II trial to evaluate AERAS-404 in 990 adolescents who have previously been vaccinated with Bacille Calmette-Guerin (BCG) as infants. Subjects will receive AERAS-404, placebo or revaccination with...
07:00 , Mar 24, 2014 |  BC Week In Review  |  Company News

Japan BCG, Astellas, Dainippon Sumitomo, Eisai, Merck KGaA, Aeras, Drugs for Neglected Diseases initiative (DNDi), Liverpool School of Tropical Medicine (LSTM),

The Global Health Innovative Technology (GHIT) awarded $12.5 million as part of the second round of awards to four partnerships developing drugs and vaccines to treat schistosomiasis, Chagas disease, parasitic roundworms and tuberculosis. The awards...
07:00 , Mar 17, 2014 |  BC Week In Review  |  Company News

Emergent BioSolutions, Valneva deal

Valneva transferred a license to develop vaccines for tuberculosis (TB) using its EB66 cell line to Emergent from the Oxford-Emergent Tuberculosis Consortium (OETC) Ltd. Valneva said financial terms of the deal were not disclosed but...
08:00 , Feb 3, 2014 |  BC Week In Review  |  Company News

Japan BCG, Dainippon Sumitomo, Aeras, National Institute of Biomedical Innovation deal

Create Vaccine Co. Ltd. - a JV between Dainippon and Japan BCG - and the institute announced they signed a formal partnership with the foundation to jointly develop mucosal tuberculosis vaccines based on the institute's...
08:00 , Dec 19, 2013 |  BC Innovations  |  Translation in Brief

Translational tidbits

Consorting with academia GlaxoSmithKline plc has set up an immuno-oncology consortium that invites academics from six cancer centers to view its nonpublic early pipeline programs and share ideas for new therapeutic candidates. The Oncology Clinical...